gallocatechol has been researched along with Cancer of Stomach in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joo, YE; Jung, YD; Khoi, PN; Lang, SA; Lee, YH; Park, JS; Stoeltzing, O | 1 |
| Morris, K | 1 |
2 other study(ies) available for gallocatechol and Cancer of Stomach
| Article | Year |
|---|---|
EGCG inhibits recepteur d'origine nantais expression by suppressing Egr-1 in gastric cancer cells.
Topics: Animals; Catechin; Cell Line, Tumor; DNA-Binding Proteins; Early Growth Response Protein 1; Enzyme Activation; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Plant Extracts; Promoter Regions, Genetic; Receptor Protein-Tyrosine Kinases; RNA Interference; RNA, Small Interfering; Stomach Neoplasms; Tea; Tetradecanoylphorbol Acetate; Transcription, Genetic; Xenograft Model Antitumor Assays | 2013 |
Tea chemicals confirmed as cancer-busting compounds.
Topics: Case-Control Studies; Catechin; Cohort Studies; Esophageal Neoplasms; Flavonoids; Humans; Male; Middle Aged; Phenols; Polymers; Prospective Studies; Stomach Neoplasms; Tea | 2002 |